Artwork
iconShare
 
Manage episode 492394570 series 3276203
Content provided by TD Securities and TD Cowen. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by TD Securities and TD Cowen or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.

Recorded on 06/03/25

TD Cowen's Machine Medicine: AI & Health Care podcast series takes on the cross-sector revolution in artificial intelligence and breaks it down one piece at a time. We highlight some of the biggest misconceptions about how AI is and can be used in different health care settings and aim to contextualize the latest and most impactful developments in a field defined by rapid innovation.

In this episode, TD Cowen's Health Care Analyst Brendan Smith hosts Sean McClain, Chief Executive Officer and Founder of Absci, to dive deeper into the world of monoclonal antibodies and how Absci's gen AI-powered drug design engine tackles the challenge of creating better drugs against harder-to-treat targets. We discuss the history of developing biologics, where this technology could take us over the very near term, and why this modality is the perfect target for the integration and revolution of AI.

https://go.td.com/PodcastDisclosure

  continue reading

289 episodes